A5012040437- Diet and metabolism studies
- Pharmacology and Obesity Treatment
- Diabetes Treatment and Management
- Metabolism, Diabetes, and Cancer
- Regulation of Appetite and Obesity
- Nutrition, Genetics, and Disease
- Dietary Effects on Health
- Bariatric Surgery and Outcomes
- Venous Thromboembolism Diagnosis and Management
- Obesity, Physical Activity, Diet
- Eating Disorders and Behaviors
- Atrial Fibrillation Management and Outcomes
- Cancer and Skin Lesions
- Medication Adherence and Compliance
- Adipokines, Inflammation, and Metabolic Diseases
- Chronic Myeloid Leukemia Treatments
- Porphyrin Metabolism and Disorders
- Health and Wellbeing Research
- Pancreatic function and diabetes
- Clinical Nutrition and Gastroenterology
- Parathyroid Disorders and Treatments
- Biochemical Analysis and Sensing Techniques
- Gallbladder and Bile Duct Disorders
- Pharmaceutical Economics and Policy
- Attachment and Relationship Dynamics
Texas Tech University Health Sciences Center
2022-2025
Texas Tech University
2022-2025
Mayo Clinic in Arizona
2022-2024
Mayo Clinic
2022-2023
WinnMed
2021
Importance No retrospective cohort study has assessed the effectiveness of semaglutide at doses used in randomized clinical trials to treat obesity (ie, 1.7 and 2.4 mg). Objective To weight loss outcomes associated with treatment for patients overweight or obesity. Design, Setting, Participants This study, conducted a referral center management, retrospectively collected data on use adults between January 1, 2021, March 15, 2022, follow-up up 6 months. A total 408 body mass index (BMI) 27...
Background: Pulmonary embolism (PE) is a frequent cause of death. Acute PE may be treated either with full anticoagulation (AC) alone or thrombolytic therapy systemic tissue-- type-plasminogen-activator (tPA) based on risk assessment. Currently, AC the standard care for most patients intermediate-high-risk PE, low-dose tPA emerging as an effective alternative. However, studies directly comparing efficacy and safety to are lacking in this patient population. Objective: The aim study was...
Abstract Aims To compare weight loss outcomes between patients starting semaglutide who had previously been on another anti‐obesity medication (AOM) compared to those were AOM‐naïve. Materials and Methods We performed a retrospective study in with overweight or obesity taking for duration of 3 12 months. Our primary endpoint was assessment percentage total body (TBWL) started as their first AOM (AOM‐naïve) taken (non‐AOM‐naïve). The secondary outcome comparison the proportions achieving ≥5%,...
Escherichia (E.) coli pneumonia is a rare infection commonly presenting with cavitary lesion. We report case of 44-year-old Hispanic male comorbidities who was admitted to our facility multiple falls for two days, shortness breath, continuous diarrhea, and urinary urgency. Lab results showed leukocytosis neutrophil predominance, anemia, respiratory alkalosis. The patient also noted have uncontrolled diabetes mellitus an A1c 17.6%. Prior admission the medical intensive care unit (MICU),...
/Objectives: Obesity is a risk factor for COVID-19 infection severity and mortality. Anti-obesity medications (AOM) are effective weight loss. However, loss outcomes with AOM during the pandemic yet to be described./Methods: Between January 1, 2016, June 30, 2021, total of 966 patients were prescribed long-term FDA-approved AOMs at Mayo Clinic. From these patients, 711 did not meet inclusion criteria. A 255 included.We performed retrospective systematic review electronic medical records...
Direct oral anticoagulants (DOACs) have become the standard of care for acute and long-term therapy venous thromboembolism (VTE) due to their efficacy safety profiles. The 2021 International Society on Thrombosis Haemostasis guidelines recommend using DOAC dosages in patients with BMI >40 kg/m2 or weight >120 kg. Use DOACs remains uncertain morbidly obese VTE, including PE. A woman her 30s who presented worsening dyspnea was diagnosed intermediate-high risk pulmonary embolism concomitant...
Hunger, satiation, postprandial satiety, and hedonic eating constitute key food intake parameters. We aim to study whether these symptoms are associated with gastrointestinal (GIS) in patients obesity.
Introduction: Obesity is a multifactorial disease with multiple associated comorbid condition including non-alcoholic fatty liver (NAFLD). Semaglutide currently the most effective anti-obesity medication that demonstrated significant weight loss outcomes in patients overweight or obesity. Limited data present regarding real-world effect of semaglutide on function tests (LFT). We aim to assess 12-months and LFT NAFLD. Methods: performed multi-centered cohort study NAFLD BMI≥ 27 kg/m2 taking...
Introduction: Rapid gastric emptying and large fasting volume in obesity can cause increased food intake appetite, leading to energy imbalance obesity. To address this, interventions like anti-obesity medications, bariatric endoscopy, surgery alter functions motility. A lifestyle intervention based on phenotypes has been shown result greater weight loss. We aim investigate the link between time 12-week loss, with a focus patients rapid emptying. Methods: Patients (BMI ≥30kg/m2) were invited...
Introduction: Obesity is a major risk factor for the development of dyslipidemia, type-2 diabetes mellitus (T2DM), hypertension (HTN), and obstructive sleep apnea. These comorbidities are associated with an increased cardiovascular disease (CVD), representing leading cause death globally. Hence, there significant need to prevent CVD by targeting excess adiposity in patients obesity. Semaglutide recently approved anti-obesity medication whose impact without T2DM not well established. We aim...
Cytarabine is an antimetabolite used in the treatment of acute myeloid leukemia which acts by inhibiting DNA synthesis and subsequently cell division. It works on rapidly dividing cells, for that reason, it affects cancer bone marrow skin cells. has variable cutaneous side effects, most common one palmar-plantar erythema usually presents with a tingling sensation around 5-7 days after cytarabine initiation, followed tenderness. Auricular rare subtype involving bilateral ears often as ear...